For the Inventor, By the Inventor

Enter inventor name

Basel, Switzerland

Giuseppe Cecere

USPTO Granted Patents = 14 (Patent Applications = 11)

CIPO Patents = 3 (Patent Applications = 7)

EPO Patents = 11 (Patent Applications = 20)

Average Co-Inventor Count = 6.8

ph-index = 2

Forward Citations = 12(Granted Patents)

Company Filing History:

12 out of 4,942

Hoffmann-la Roche Inc.

Years Active: 2015-2025

where 'Filed Patents' based on already Granted Patents

14 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12365687 - Benzodiazepine derivatives as GABA A gamma 1 PAM (2025-07-22),

2. 12344614 - Benzodiazepine derivatives as GABA a GAMMA1 PAM (2025-07-01),

3. 11840528 - Isoxazolyl ether derivatives as GABAα5 PAM (2023-12-12),

4. 11739095 - Substituted benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepines as GABA A GAMMA1 positive allosteric modulators (2023-08-29),

5. 11091471 - Isoxazolyl ether derivatives as GABAα5 PAM (2021-08-17),

6. 10316036 - Substituted pyrazino[2,2-a]isoquinoline derivatives (2019-06-11),

7. 10023559 - Substituted azetidine derivatives (2018-07-17),

8. 9957261 - 6-amino-5,6,7,8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives (2018-05-01),

9. 9840501 - Morpholin-pyridine derivatives (2017-12-12),

10. 9828374 - Substituted pyrazino[2,2-a]isoquinoline derivatives (2017-11-28),

11. 9808456 - Piperazine thiazole derivatives useful in the treatment of tauopathies such as Alzheimer's disease (2017-11-07),

12. 9790230 - 2-oxa-5-azabicyclo[2.2.1]heptan-3-yl derivatives (2017-10-17),

13. 9663530 - 5-oxa-2-azabicyclo[2.2.2]OCTAN-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives (2017-05-30),

14. 9187440 - Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease (2015-11-17),

Title: The Innovative Contributions of Giuseppe Cecere

Introduction

Giuseppe Cecere is a prominent inventor based in Basel, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds for neurological disorders. With a total of 14 patents to his name, Cecere's work has the potential to impact the treatment of various cognitive and neurological conditions.

Latest Patents

Cecere's latest patents include innovative benzodiazepine derivatives that act as GABA A gamma 1 positive allosteric modulators (PAM). These inventions provide novel heterocyclic compounds with specific general formulas, along with their pharmaceutically acceptable salts. The patents also detail pharmaceutical compositions that incorporate these compounds, processes for manufacturing them, and methods for their use as medicaments. These compounds are particularly aimed at treating or preventing acute neurological disorders, chronic neurological disorders, and cognitive disorders.

Career Highlights

Throughout his career, Cecere has worked with notable companies in the pharmaceutical industry, including Hoffmann-La Roche Inc. and Remynd NV. His experience in these organizations has allowed him to refine his expertise in drug development and innovation.

Collaborations

Cecere has collaborated with esteemed colleagues such as Guido Galley and Roger David Norcross. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Giuseppe Cecere's innovative work in the pharmaceutical field, particularly in the development of benzodiazepine derivatives, showcases his commitment to improving treatments for neurological disorders. His contributions are significant and continue to influence the industry.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…